CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Summit Therapeutics Inc (Old) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Summit Therapeutics Inc (Old)
2882 Sand Hill Road, Suite 106
Phone: (617) 514-7149p:617 514-7149 MENLO PARK, CA  94025  United States Ticker: SUMMSUMM
Business Summary
Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20201/31/2019Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Co-Chief Executive Officer Robert W.Duggan 78 7/26/2022 12/30/2019
President, Co-Chief Executive Officer, Director MahkamZanganeh 51 7/26/2022 11/11/2020
Chief Financial Officer AnkurDhingra 46 6/1/2022 6/1/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Discuva Limited The Merrifield Centre Rosemary Lane Cambridge United Kingdom

Business Names
Business Name
Discuva Limited
MuOx Limited
SMMT
12 additional Business Names available in full report.

General Information
Number of Employees: 61 (As of 1/31/2019)
Outstanding Shares: 672,319,022 (As of 3/31/2020)
Stock Exchange: LON
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023